Angiotensin receptor neprilysin inhibitor LCZ696: pharmacology, pharmacokinetics and clinical development.

about

Angiotensin receptor neprilysin inhibitor LCZ696: pharmacology, pharmacokinetics and clinical development.

Item

http://www.wikidata.org/entity/Q38790076

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Angiotensin receptor neprilysi ...... tics and clinical development.

@en

type

Item

label

Angiotensin receptor neprilysi ...... tics and clinical development.

@en

prefLabel

Angiotensin receptor neprilysi ...... tics and clinical development.

@en

P1476

Angiotensin receptor neprilysi ...... tics and clinical development.

@en

P2093

Bin Liu

http://www.w3.org/2001/XMLSchema#string

Bing H Wang

http://www.w3.org/2001/XMLSchema#string

Christopher Reid

http://www.w3.org/2001/XMLSchema#string

Darren J Kelly

http://www.w3.org/2001/XMLSchema#string

Ian Wang

http://www.w3.org/2001/XMLSchema#string

Yingchun Zhou

http://www.w3.org/2001/XMLSchema#string

Yue Hua

http://www.w3.org/2001/XMLSchema#string

P2860

Hydrolysis of iodine labelled urodilatin and ANP by recombinant neutral endopeptidase EC. 3.4.24.11

Valsartan lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease

Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics

Engineering Neprilysin Activity and Specificity to Create a Novel Therapeutic for Alzheimer’s Disease

Effect of nesiritide in patients with acute decompensated heart failure

Angiotensin-neprilysin inhibition versus enalapril in heart failure

On the role of endothelin-converting enzyme-1 (ECE-1) and neprilysin in human breast cancer

Heart disease and stroke statistics--2014 update: a report from the American Heart Association

Human hypertension is characterized by a lack of activation of the antihypertensive cardiac hormones ANP and BNP.

Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study.

P304

103-115

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/FCA-2016-0057

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Danny Liew

P577

2016-11-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27892684

http://www.w3.org/2001/XMLSchema#string